SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — James Madison

PatientJames Madison
Date of birth2003-03-16
IdentifiersMRN HR-EN007-SYN; SSN (made up) 000-07-2618
Document date2026-06-11
AuthorJosiah Pembroke-Achebe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review after the diagnosis of functional/dissociative seizures. [S]

History of Present Illness

Mr. Madison returns six weeks after the diagnosis. He finished the levetiracetam taper three weeks ago; his events have not increased, and the irritability has gone. He has had four psychotherapy sessions and keeps his event diary: three events in six weeks, each shorter than before, all at the end of long study days or after poor sleep. He has begun to notice a warning feeling of distance and heaviness, and once stopped an event by grounding himself. He understands and accepts the diagnosis, and has explained it to two friends. His mood is still low most mornings and he worries a great deal about his examinations; he would like help beyond the therapy. He has had no thoughts of death or self-harm, and the rifle remains locked. He has not driven. [S]

ElementDetail
EventsThree in six weeks, shorter; one stopped by grounding
LevetiracetamStopped three weeks ago; no rebound; irritability gone
PsychotherapyFour sessions
PHQ-9 and GAD-711 and 12
SafetyNo suicidal thoughts; rifle locked; not driving

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight 54.6 kg; no fever
NeurologicalPositiveThree typical events; no new kinds of event, injury, or tongue biting
PsychiatricPositiveLow mood in the mornings and much worry; sleep about six and a half hours; no suicidal thoughts

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEGOne tablet twice dailyOral route2025-12-02 to 2026-04-30completedS
Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stopHalf a tablet twice daily for two weeks, then half a tablet at night for one week, then stopOral route2026-04-30 to 2026-05-21completedS
Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morningHalf a tablet each morning for one week, then one tablet each morningOral route2026-06-11activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-11Body height168cmS
2026-06-11Body weight54.6kgS
2026-06-11Body mass index (BMI) [Ratio]19.3kg/m2S
2026-06-11Systolic blood pressure112mm[Hg]S
2026-06-11Diastolic blood pressure70mm[Hg]S
2026-06-11Heart rate74/minS
2026-06-11Respiratory rate14/minS
2026-06-11Body temperature36.6CelS
2026-06-11Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-11Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]11{score}S
2026-06-11Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]12{score}S

Physical Exam

Vital signs recorded on 2026-06-11; see the Vital Signs section. [S]

SystemFinding
GeneralBetter kept; engaged
Mental statusMood "heavy in the mornings"; affect reactive; logical; no suicidal ideation; insight good

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causesresolvedconfirmed R40.4S — Synthetic presenting problem echoing his documented overwork, infirm health, and low spirits, and the later accounts of sudden attacks; superseded by the diagnosis at the second visit.
Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsyresolvedconfirmed Z79.899S — Synthetic medication problem for teaching about avoiding unneeded antiseizure medicines; resolved when the medicine was stopped.
Functional/dissociative seizures (psychogenic nonepileptic seizures), documented by video-EEG: two habitual events captured with eyes closed and resisting opening, fluctuating unresponsiveness, and a normal waking EEG throughout, with no ictal or postictal change; normal interictal EEG and brain MRI; epilepsy and syncope excludedactiveconfirmed F44.5S — Synthetic modern diagnosis. His infirm health, overwork, and low spirits in youth are documented (D); retrospective explanations of his later attacks, including epilepsy, are disputed (R). This record does not assert what his attacks were.
Generalized anxiety disorder: worry about his future, his health, and his studies most days for more than a year, with restlessness, poor sleep, and muscle tension (GAD-7 14 at intake)activeconfirmed F41.1S — Synthetic diagnosis made at the neuropsychiatric assessment during video-EEG monitoring.
Major depressive disorder, single episode, moderate: low mood, loss of interest, poor sleep and concentration, and a sense that he will not live long, for about eighteen months (PHQ-9 13 at intake); no suicidal ideation or intentactiveconfirmed F32.1S — Synthetic diagnosis echoing, without asserting, his documented letter expecting an early death.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today11, down from 13 at intake; item 9 scored 0
SurveyGAD-7With the PHQ-9 when anxiety accompanies depressionCompleted today12, down from 14
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior; rifle locked; protective factors unchanged
ExaminationEvent diary: frequency, duration, triggers, warning sensations, and injuriesEvery visitCompleted todayThree events in six weeks, shorter, linked to long study days and poor sleep; one interrupted by grounding; no injuries
Medication safetyAntiseizure medicine reviewAt diagnosis and until withdrawnCompleted todayTaper completed three weeks ago with no rebound in events
Medication safetySSRI tolerability check two weeks after starting2 weeks after starting and after each dose changeDueSertraline starts today; nurse telephone check booked for two weeks
ReferralCBT-informed psychotherapy for functional seizuresWeekly during the courseCompleted todayFour of twelve sessions attended
Self-managementDrivingEvery visit until clearedCompleted todayNot driving
Self-managementSleep, studies, and first-aid planEvery visitCompleted todaySleeping about six and a half hours; agreed to stop studying by 10 pm; testing accommodations requested
LaboratoryLithium, anticonvulsant mood-stabilizer, or antipsychotic monitoringOnly on those drugsNot indicatedNot taking any; no bipolar features

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014); Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020); Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Nurse telephone check in two weeks; preventive visit next month; three-month review. Next scheduled visit 2026-07-16: preventive health visit at 23. [S]